Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care. - Geller JA; Pacilio R; Downey AE; Ragnhildstveit A; Raymond-Flesch M; Knatz-Peck S; Gukasyan N. (2026)

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM. - Beidas Z; Ragnhildstveit A; Blackman A; Anderson T; Fewster E; Syed OA; Sobolenko V; Kanca IK; Son T; Farb N; Petranker R. (2026)

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial. - van der Vaart A; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Suppes T; Sackeim HA; Aaronson ST. (2026)

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization. - Yu F; Tafur J; Moreno F; Dahmer S. (2026)

A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. - Francisco A Moreno (ClinicalTrials.gov, 2026)

Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder - COMPASS Pathways (ClinicalTrials.gov, 2026)

Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin - Kosiarski Bartłomiej; Skrzypek Anna; Markowicz Patrycja; Zbrożek Mikołaj; Biłyk Krzysztof; Hutkowski Maciej; Chwostek Zuzanna; Maruchniak Hanna; Marzec Wiktoria; Biedroń Paulina (Journal of Pre-Clinical and Clinical Research, 2026)

Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review - Walters CK; Chetty S; Rants’o TA; Gossayn S; Lerotholi LJ. (Research Square, 2026)

Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration. - Jóźwiak-Bębenista M; Stasiak A; Sienkiewicz M; Kwiatkowski P; Kowalczyk E. (2026)

The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD. - University Medical Center Groningen (ClinicalTrials.gov, 2026)

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT - Tarailis P; Griskova-Bulanova I. (bioRxiv, 2026)

1020 Long-term Impact of Psilocybin Administration on Sleep-Continuity via Wearable Sensor Time-series: Preliminary-results in Post-Treatment Lyme Disease - Reid Matthew; Yaffe Abigail; Geithner Ian; Rebman Alison; Aucott John; Garcia-Romeu Albert (SLEEPJ, 2026)

1080 Psilocybin Elicits Non-Linear Night to Night Changes in Sleep Spectral Power - Reid Matthew; Weisman Eli; Martinez Luis Luna; Coon William; Barrett Frederick (SLEEPJ, 2026)

0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study - Vidot Denise; Diggs Bria-Necole; Baral Amrit; Thompson Michelle; Jean-Louis Girardin (SLEEPJ, 2026)

Neural correlates of insight on psilocybin: a within-subjects, healthy volunteer study - Pasquini Lorenzo; Girn Manesh; Kettner Hannes; Ostrand Avery; Allison Kate; Valtierra Christian; Lucas Will; McConnell Patrick; Miller Catriona; Griffith Sydney; Weinstein Dawn; Anderson Brian; et al. (JoCN Forum, 2026)

Exploring new avenues: Psychedelic-assisted therapy for young people. - Vamvakopoulou IA; Nicholls D; Nutt DJ; Di Simplicio M. (2026)

Does Psilocybin Require Psychedelic Effects to Treat Depression? A4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review - Zachar Kinga; Sito Maksymilian; Jurkowski Filip; Wójcik Łukasz; Gawron Natalia; Bojanowski Hubert Tomasz; Dobracka Aleksandra; Marczak Zuzanna; Jarowicz Monika; Czmyr Jędrzej (Journal of Education, Health and Sport, 2026)

Magic mushroom compound shows promise against cocaine addiction. - Nuwer R (Science (New York, N.Y.), 2026)

The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus. - Forsyth D; Faraone N; Lamarre SG; Currie S. (2026)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer - Sunstone Medical (ClinicalTrials.gov, 2026)

Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study - University of North Carolina; Chapel Hill (ClinicalTrials.gov, 2026)

A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder - Stanford University (ClinicalTrials.gov, 2026)

An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers - University of Nebraska (ClinicalTrials.gov, 2026)

Human brain changes after first psilocybin use. - Lyons T; Spriggs M; Kerkelä L; Rosas FE; Roseman L; Mediano PAM; Timmermann C; Oestreich L; Pagni BA; Zeifman RJ; Hampshire A; Trender W; et al. (2026)

A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control - Usona Institute (ClinicalTrials.gov, 2026)

A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression - University of Washington (ClinicalTrials.gov, 2026)

Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury - James J. Peters Veterans Affairs Medical Center (ClinicalTrials.gov, 2026)

Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder - University of California; Los Angeles (ClinicalTrials.gov, 2026)

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults. - Yang KH; Satybaldiyeva N; Kepner W; Friedman J; Ping S; Leas EC. (2026)

Effects of Psilocybin Treatment on Cognitive Effort Avoidance in Major Depressive Disorder and Co-Occurring Alcohol Use Disorder - Sayali Ceyda; Weisman Eli; Barrett Frederick (JoCN Forum, 2026)

Effects of psychedelic use on authoritarian attitudes revisited. - Simonsson O; Lyons T; Marks J; Kettner H; Roseman L; Haijen E; Kaelen M; Carhart-Harris R. (2026)

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial - Lakshmi N Yatham (ClinicalTrials.gov, 2026)

Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects - Yale University (ClinicalTrials.gov, 2026)

Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS - Mauney Erin; Zambrano Juliana; Clukey Jenna; Burton-Murray Helen; Datko Michael; Napadow Vitaly; Kuo Braden; King Franklin (Gastrointestinal Endoscopy, 2026)

Sex-Specific Effects of Psilocin on Paraventricular Nucleus of the Thalamus (PVT) Circuitry and Threat Responding Behavior in Male and Female Rats - Herman Melissa (Biological Psychiatry, 2026)

Prohedonic Effects of Psilocybin (COMP360) in a Touchscreen-Based Rodent Probabilistic Reward Task (Abstract ID: 227883) - LaMalfa Kayleigh; Pizzagalli Diego A.; Bergman Jack; Thomas Christopher W.; Kangas Brian (The Journal of Pharmacology and Experimental Therapeutics, 2026)

Acute Effects of 4-Bromo-2,5-Dimethoxyphenethylamine (2C-B) Compared With Psilocybin and MDMA in Healthy Participants - Holze Friederike; Arikci Denis; Thomann Jan; Rudin Deborah; Luethi Dino; Liechti Matthias E. (Biological Psychiatry, 2026)

PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554) - Hayduk Sean; Stringer Amy; Zagorski Satoria; Ward Sara Jane (The Journal of Pharmacology and Experimental Therapeutics, 2026)

Profiling the Cell-Type Specific Effects of Psilocybin in Medial Prefrontal Cortexh - Schuler Heike; Zhou Delong; Savignac Chloé; Cvetkovska Vedrana; Tse Yiu-Chung; Meccia Juliet; Bzdok Danilo; Bagot Rosemary (Biological Psychiatry, 2026)

356. Psilocybin Therapy is Associated With Decreases in Markers of Mitochondrial Stress and Inflammation in an Open-Label Clinical Trial of Parkinson’s Disease - Bradley Ellen; Kelley D Parker; Picard Martin; Szigeti Balazs; Sakai Kimberly; Fernandes Gisele; Ostrem Jill; Tanner Caroline; Finley Patrick; Ludwig Connie; Llerena Katiah; Busby Zach; et al. (Biological Psychiatry, 2026)

483. Acute Functional Brain Changes Associated With Psilocybin in Depression and Healthy Adults: A Systematic Review and Coordinate-Based Meta-Analysis - Poulin Joshua; Viulet Nic; Liu Ashley; MacIntosh Bradley J.; Nestor Sean M. (Biological Psychiatry, 2026)

Pure psilocybin reduces reward-associated preference while mushroom extract shows transient exploratory effects in rats (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

C29-12 Psilocybin Treatment Could Improve Outcomes for Age-associated Lung Diseases - Hecker L; Kleinhenz J M; Coarfa C; Kato K (American Journal of Respiratory and Critical Care Medicine, 2026)

Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA - Yockey R. Andrew; Amis Amber; Devier Elise; Apu Aminul; Hoopsick Rachel (AJPM Focus, 2026)

Effects of Psilocybin on Attentional Set-Shifting Following Chronic Unpredictable Stress in Rats (Abstract ID: 231339) - Hennessey Joseph; Mantsch John; McCorvy John (The Journal of Pharmacology and Experimental Therapeutics, 2026)

Preclinical evaluation of psilocybin and related compounds: Inhibition of cytochrome P450 isoforms (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS - Mauney Erin; Zambrano Juliana; Clukey Jenna; Burton-Murray Helen; Datko Michael; Napadow Vitaly; Kuo Braden; King Franklin (Gastroenterology, 2026)

SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models - Signor Anna; Colognesi Martina; Finzi Giovanna; Gabbia Daniela; Mattarei Andrea; Comai Stefano; Pasut Gianfranco; Folli Franco; Manfredi Paolo; De Martin Sara (Journal of Hepatology, 2026)

6. Open-Label Extension of Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Continued Safety and Short-Term Efficacy Signal for Drinking, Craving, and Self-Efficacy - Pagni Broc; Ross Stephen; Kim Yuna; Bogenschutz Michael (Biological Psychiatry, 2026)

Cytochrome P450 Inhibition by Psilocybin and Psilocin: A Combined Molecular Dynamics and Enzymatic Screening Study (RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia, 2026)

Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical - Gupta Gyandev; Yadav Ravina (JOURNAL OF ADVANCE AND FUTURE RESEARCH, 2026)

Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review. - Viljoen G; Walter H; Bendau A; Koslowski M; Betzler F (Journal of psychopharmacology (Oxford, England), 2026)

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial. - Mertens LJ; Koslowski M; Betzler F; Brand M; Evens R; Kärtner L; Jungaberle A; Jungaberle H; Majic T; Schmitz CN; Ströhle A; Scharf D; et al. (2026)

Enlightenment in a Pill-Testing the Efficacy of Psilocybin. - Hudson JI; Pope HG. (2026)

Trip killers: Addressing a critical knowledge gap in psychedelic research. - O'Mahony B; Harrington C; Harkin A; Lally N (Journal of psychopharmacology (Oxford, England), 2026)

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial. - Hendricks PS; Lappan SN; Shelton RC; Lahti AC; Cropsey KL; Johnson MW; Bradley M; Simonsson O; Davis LL; Grossman DH; Ortiz CE. (2026)

Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder-A Critical Appraisal. - Bonar EE. (2026)

Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study. - Filiz ES; Stringer D; Kellermann V; Olive RR; Said O; Mutwalli H; Bektas S; Akkese MN; Ireland K; Beishon-Murley D; Khor JWT; Allman L; et al. (Health technology assessment (Winchester, England), 2026)

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial. - Yngwe H; Plavén-Sigray P; Ekman CJ; Henje E; Berglund A; Tiger M; Beckman M; Lundberg J. (2026)

New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants. - Silva MH. (2026)

Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence. - Hajivalizadeh S; Farahmand K; Kazemzadeh K; Hajivalizadeh G; Shamabadi A. (2026)

Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae. - Kwiatos N; Ossel S; Mutti FG. (2026)

Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake. - Bergh MS; Bogen IL; Vevelstad M; Øiestad ÅML. (2026)

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption. - Briggs D; Sease TB; Menou R; Perkins DR. (2026)

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study) - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2026)

A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain - Joshua Woolley; MD; PhD (ClinicalTrials.gov, 2026)

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder - Marini S; De Berardis D. (Preprints.org, 2026)

A128-Channel Wireless Wearable Myolink (W2 Myolink): Functional Characteristics and Multidisciplinary Experiments - Zajaczkowski M; Koutsoftidis S; Sheeraz M; Barsakcioglu DY; Jia T; McGeady CA; Kundu A; Pizzi M; Tatti F; Bashford J; Bhavesh P; Farina D; et al. (Research Square, 2026)

Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review. - Magnani L; Ghirotto L; Fesce F; Re T; Tanzi S; Amerio A; Costanza A. (2026)

Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study. - Rockhill KM; Bemis EA; Schow N; Olsen HA; Beekman K; Fox EJ; Monte AA; Black JC. (2026)

"Large-Scale and Local Functional Connectivity Changes Following Psilocybin Administration in Methamphetamine Use Disorder. - Chaganti J; Siefried KJ; Vyakaranam VS; Acheson L; Brett J. (2026)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia. - Askey T; Allen-Ross D; Luzyanin D; Lasrado R; Gilmour G; Hunt SP; Tamagnini F; Ahmed M; Stephens GJ; Maiarú M. (2026)

Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations - Salinsky LM; Fox JL; Diaz KC; Timmons BC; Ferguson SM. (Research Square, 2026)

Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects. - Low ZXB. (2026)

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder - Portland VA Research Foundation; Inc (ClinicalTrials.gov, 2026)

A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD) - Usona Institute (ClinicalTrials.gov, 2026)

Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy - Kyle Greenway (ClinicalTrials.gov, 2026)

Distinct Modulatory Effects on Affective Biases by Different Serotonergic Psychedelics and MDMA in Male Rats: Possible Implications for Antidepressant Effects - Hinchcliffe JK; Bartlett J; Thomas CW; Golden CT; Gilmour G; Bortolotto ZA; Robinson ES. (bioRxiv, 2026)

Psilocybin as an alternative to conventional treatments: A systematic review - Cahuasqui-Mendoza Deivid Antonio (Gaceta Médica de Caracas, 2026)

Prevalence and Correlates of Past-Year Psilocybin Use in the United States. - Yang KH; Eun A; Palamar JJ. (2026)

Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site. - Baral A; Pan Y; Hlaing WM; Garcia-Romeu A; Pinheiro PS; Vidot DC. (2026)

Wherefore the Magic? The Evolutionary Role of Psilocybin in Nature. - Matthews Nicholass KJ; Flis I; Hanley ME; Knight ME; Lane SM; Littlejohn G; Thom MDF; Billington RA; Boden R; Cummins R; Green BJ; Griffin C; et al. (2026)

Metastability of resting-state bold fMRI as a reliable biomarker of individual brain dynamics: An interrogation of within-subject variability as a function of total acquisition time. - Sheheitli H; Hermosillo R; Grimsrud G; Madison T; Dominguez OM; Nelson S; Fair D; Nahas Z. (2026)

Structural plasticity and enhanced fear extinction following psilocybin in chronically stressed mice - Knox CA; Woodburn SC; Gilbert AD; Schlotzhauer JM; Kwan AC. (bioRxiv, 2026)

A25-year analysis of Armillaria (honey mushroom) poisoning in Wisconsin. - Feldman R; Audette M; Leacock PR; Theobald J. (2026)

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission - University of Colorado; Denver (ClinicalTrials.gov, 2026)

The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes - Khosravi Mohsen; De Berardis Domenico; Tusconi Massimo (Mental Wellness, 2026)

Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials - Siti Nashria Rusdhy; Andrian Fajar Kusumadewi; Carla Raymondalexas Marchira; Mustika Suci Mahardikaningrum; Teresa Lalita Wiryarini; Devira Ayu Wulandari (Open Access Indonesian Journal of Medical Reviews, 2026)

Serotonergic Polypharmacology of 2-Halogenated Tryptamines - Yacoub J; Bray E; Bayyat J; Glatfelter GC; Leake A; Buitrago EM; Maitland AD; Partilla J; Cavalco NG; Schalk SS; Lammers JC; Baumann MH; et al. (bioRxiv, 2026)

Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins. - Drange S; Cohen J; Johansen SS; Dunkley B; Palner M. (2026)

Open Label Psilocybin Brain Stimulation and Imaging Pilot Study - Johns Hopkins University (ClinicalTrials.gov, 2026)

Comparative Medico-Legal Frameworks for Psilocybin Regulation: A March 2026 Update - Brinzei OV. (Preprints.org, 2026)

Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats. - Bysiek A; Szpręgiel I; Wojtas A; Maćkowiak M; Wawrzczak-Bargieła A; Leśkiewicz M; Trojan E; Kamińska K; Kumorek W; Bilecki W; Gołembiowska K. (2026)

Psychedelics and Autism Therapy: A Review of Current Research and Future Directions. - Gondi CS; Gnanamony M; Gondi TP; Nersesyan L; Demirkhanyan L. (2026)

Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND) - King's College London (ClinicalTrials.gov, 2026)

Psilocybin reshapes cortical inhibition through selective interneuron recruitment - Davoudian PA; Jiang Q; Knox CA; Savalia NK; Shao L; Wilson J; Weiner AM; Chong CW; Liao C; Nothnagel JD; Sakurai T; Kwan AC. (bioRxiv, 2026)

Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs. - Norris JJ. (2026)

Psilocybin’s Kinematic Effect on Manual Dexterity - Klintefors P; Bhagavan C; Kanaan R; Bryson A; Berlowitz D; Attard Z; Carter O. (Research Square, 2026)

Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration - Jóźwiak-Bębenista M; Stasiak A; Sienkiewicz M; Kwiatkowski P; Kowalczyk E. (Preprints.org, 2026)

Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey - Vélez Rodríguez Jean C.; Duquesne-Maldonado Yanice; Hernández Torres Julián M.; Da'Luz Sant'Ana Istoni; Nazario Cruz M. (Journal of Psychedelic Studies, 2026)

Effects of a single dose of psilocybin on diet-induced weight loss in obese mice. - Keenan RJ; Haque RT; Jin X; Mustafa T; Homman-Ludiye J; Elysee K; Wee ZS; Simonds SE; Foldi CJ; Cowley MA. (2026)

A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience. - Back AL; McGregor BA; Thorn LL; Harvey K; Blom D; Callan G; Guy J; Kumar S; Hershberg R; Layer M; Levin J; Myers S; et al. (2026)

CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial - Section for Affective Disorders; Northern Stockholm Psychiatry (ClinicalTrials.gov, 2026)

Psilocybin acutely reduces low-frequency BOLD power and frequency-specific connectivity - Olsen AS; Larsen K; McCulloch DE; Ganz M; Madsen MK; Ozenne B; Knudsen GM; Rehman Nu; Fisher PM. (bioRxiv, 2026)

Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol - Penberthy J. Kim; A. Wise Fatma; Cherup Nicholas; Penberthy J. Morgan; Mitchell Evaline; Burns Madeline; Akinlade Oluwafunmilayo; Chung David; Parmar Harshit; Singer Jonathan (Psychoactives, 2026)

The astrocytes in the prefrontal cortex contribute to the rapid antidepressant-like effects of psilocybin in the chronic restraint stress mouse model. - Qiao YX; Dai W; Yao YS; Wei QQ; Yue CX; Yin YY; Li YF; Zhang LM. (2026)

Observing the mind under psychedelics: conceptual metaphors used following four once-weekly macrodoses of psilocybin - Rundquist Eric; Monasterio López Diego Nicolás; Oyarzo Alvarado Juan Jonathan; Carhart-Harris Robin; Pasquini Lorenzo; Vinson Erin; Girn Manesh; Ostrand Avery; Allison Kate; Kettner Hannes; Miller Catriona; Griffith Sydney; et al. (Philosophical Psychology, 2026)

Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat. - Veysi A; Atanasovski D; Ardalan M; Motamed N; Eriksson E. (2026)

Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration. - Effinger DP; Hoffman JL; Quadir SG; Rollison CS; Toedt D; Echeveste Sanchez M; High MW; Hodge CW; Herman MA. (2026)

Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression. - Morel NS; Stenbaek DS; Lundberg J; Beckman M. (2026)

Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024. - Rumph JT; Winquist A; Troeschel AN; Pulver S; Schnall AH; Ebersole J; Yeh M; Burt B; Federman SL; Klontz K; Dasenbrock C; Leahy HL; et al. (MMWR. Morbidity and mortality weekly report, 2026)

Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin - Baker JJ; Kogan E; Ma S; Lu J; Zuo Y. (bioRxiv, 2026)

Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder - University of California; Los Angeles (ClinicalTrials.gov, 2026)

Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks - Including Life Between Lives and Transpersonal Hypnotherapy - Gallardo LM. (Preprints.org, 2026)

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations. - Marazziti D; Gambini M; Gurrieri R; Russomanno G; Sità G; Pescini E; Digiuseppe FR; Mucci F. (2026)

A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression - Singleton S. Parker; Sevchik Brooke L.; Lahey Analiese; Cuijpers Pim; Harrer Mathias; Jones Megan T.; Nayak Sandeep M.; Strain Eric C.; Vandekar Simon N.; Dworkin Robert H.; Scott J. Cobb; Satterthwaite Theodore D. (Nature Mental Health, 2026)

An international mega-analysis of psychedelic drug effects on brain circuit function. - Girn M; Doss MK; Roseman L; Preller KH; Palhano-Fontes F; Pasquini L; Barrett FS; Mallaroni P; Mason NL; Timmermann C; McCulloch DE; Fisher PM; et al. (2026)

Catatonia Associated With First-Time Psilocybin Exposure: A Case Report. - Singh J; Mruthyunjaya P. (2026)

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study) - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

Psilocybin and human longevity. - Lerer L. (2026)

Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2026)

Effects of Psilocybin in Obsessive Compulsive Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

265 Self-reported rates of psilocybin use in North Florida, 2012 to present - Millay Tamara; Kodali Monica Bhargavi; Cottler Linda (Journal of Clinical and Translational Science, 2026)

361 Effect of intravenous psilocybin on mechanical hypersensitivity in a rat model of reserpine-induced chronic centralized pain - Huels Emma; Smith Sara; Liu Tiecheng; Pal Dinesh (Journal of Clinical and Translational Science, 2026)

26-CCC-15854-ACC TALK ABOUT A BAD TRIP!: PSILOCYBIN USE WITH PRE-EXISTING CARDIOVASCULAR DISEASE, A CASE REPORT - Buchanan Christine (JACC, 2026)

MedCheck: FDA Approves Novel Antipsychotic Milsaperidone; Designates Psilocybin Analogue as Breakthrough Therapy for Postpartum Depression, and More! - Richmond Linda M. (Psychiatric News, 2026)

Psilocybin: Wirksam, aber kein Wundermittel. - Pichler H. (2026)

Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications - Meshkat Shakila; Jha Manish K.; Bhat Venkat (Focus, 2026)

Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use. - Bhatt KV; Friedman J; Benster L; Narasimhan R; Yang K; Mishra J; Weissman CR; Ramanathan D. (2026)

Psychedelic-Assisted Therapy: Breakthrough for Whom? - Adams DR; Xu KY; Cabassa LJ (Psychiatric services (Washington, D.C.), 2026)

Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action. - Kazdan J; Ladha KS; Husain MI. (2026)

An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder. - Grant JE; Boutouis S; O'Brien M; Avila L; Neelapu M; Ehsan D. (2026)

Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants. - Berman P; Höfer J; Mehlman H; Almekias-Siegl E; Khersonsky O; Dong Y; Heinig U; Sulimani L; Hao LK; Cohen S; Peleg Y; Meir S; et al. (2026)

Psilocybin Trends in States That Decriminalized Use. - Black JC; Bau GE; Cook RR; Bemis EA; Monte AA. (2026)

Specific and Multi-Product Clade I and Clade IV Sesquiterpene Synthases Contribute to the Psilocybe cubensis Volatilome. - Schober S; Dorfmann L; Walther K; Blei F; Chadeayne AR; Gressler M; Bartram S; O'Connor SE; Hoffmeister D. (2026)

Reshaping human neurons. - Maltman JL; González-Maeso J. (2026)

In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin. - Jurowski K; Kobylarz D; Noga M. (2026)

Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling. - Albert OM; Arthur A. (2026)

Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology. - Geraci J; Viirre E; Qorri B; Pani L. (2026)

Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression - Sunnybrook Health Sciences Centre (ClinicalTrials.gov, 2026)

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder - Indiana University (ClinicalTrials.gov, 2026)

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression” - Wolff M; Kangaslampi S; Zeifman R; Spangemacher M. (PsyArXiv, 2026)

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression” (PsyArXiv, 2026)

Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin. - Smith KA; Harcourt E; Cipriani A. (2026)

Unlocking 'stuckness' and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic-assisted therapy for substance use and mental health problems. - Catchlove SJ; Oliver K; Savic M; Arunogiri S. (2026)

Associations Between Psilocybin Use Motives and Cognitive, Affective, and Behavioural Self-Stigma. - Knibb G; Ward R; Christiansen P; Roberts CA. (2026)

Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics. - Varela YM; de O Tavares VD; Delgado LM; de Faria HAT; Menezes LQ; Almeida RM; Agrícola P; de Carvalho BS; Bienemann B; Falchi-Carvalho M; Cavalcanti-Ribeiro P; Palhano-Fontes F; et al. (2026)

Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression - Federal University of Latin American Integration (ClinicalTrials.gov, 2026)

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons - Schmidt Malin; Hoffrichter Anne; Davoudi Mahnaz; Horschitz Sandra; Lau Thorsten; Meinhardt Marcus W; Spanagel Rainer; Ladewig Julia; Köhr Georg; Koch Philipp (eLife, 2026)

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. - Schmidt M; Hoffrichter A; Davoudi M; Horschitz S; Lau T; Meinhardt MW; Spanagel R; Ladewig J; Köhr G; Koch P. (2026)

Psilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory Cortex - Johnson JD; Tian R; Etemadi Y; Li Z. (bioRxiv, 2026)

Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial - Pagni BA; Ross S; Mennenga S; Bhatt SR; Zeifman R; Petridis P; Carrithers B; Worth L; Podrebarac S; Owens L; O'Donnell K; Roberts DE; et al. (PsyArXiv, 2026)

Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial (PsyArXiv, 2026)

Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors. - Mäki-Marttunen V. (2026)

Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD). - Skalski P; Pękacka-Falkowska K; Pluto-Prądzyńska A; Owecki MK. (2026)

The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial. - Anders Fink-Jensen; MD; DMSci (ClinicalTrials.gov, 2026)

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial - Medical University of Vienna (ClinicalTrials.gov, 2026)

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential. - Patil SA; Hunsberger HC. (2026)

Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review. - Gillet A; Geron C; Vitello MM; Lejeune N. (2026)

Integrated 5-HT2A -TrkB and G protein signaling in serotonergic psychedelic responses - Taddei-Tardón M; Medina-Rodríguez L; Maltman JL; Hudson S; Potukanuma S; Jiménez JH; Martín-Guerrero SM; González-Maeso J; López-Giménez JF. (bioRxiv, 2026)

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis. - Goodwin GM; Aaronson ST; Alvarez O; Carhart-Harris R; Croal M; Feifel D; Hellerstein DJ; Husain MI; Kelly JR; Kirlic N; Licht RW; Marwood L; et al. (2026)

Psilocybin, Lp(a), CAC, Niere und Darmkrebs - Evidenz-Quickies KW12 - Nößler Denis (EvidenzUpdate, 2026)

Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis. - Kishi T; Sakuma K; Hatano M; Uchida H; Iwata N. (2026)

Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies - University of New Mexico (ClinicalTrials.gov, 2026)

Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil. - Portes MAM; Bertoglio LJ. (2026)

Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy. - Anchesi I; Raffaele I; Astorino MF; Lui M; Calabrò M; Cipriano GL. (2026)

Psychological support in psychedelic-assisted therapy clinical trials: A systematic review. - Brusky B; M'Bailara K; Alla F; Barrault M. (2026)

Raman Activity Investigation and Utilization of Psilocybin - Sun Mingyu; Zhao Xiaoyu; Kong Fandi; Wang Jinsong; Lu Yunchang; Tong Liang (Journal of Raman Spectroscopy, 2026)

PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS - Komarczewska Anna; Kociński Michał; Iglewski Patryk; Pietrasz Michał; Idziński Jakub; Lubomska Anna (International Journal of Innovative Technologies in Social Science, 2026)

Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies. - Farré-Colomés À; Rublinetska O; Soto-Angona Ó. (2026)

Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution. - Matsukubo J; Friesen EL; MacDonald-Spracklin R; Iseman R; Solmi M; Fiedorowicz JG; Fischer B; Myran DT. (2026)

Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study - Gustavo Vazquez (ClinicalTrials.gov, 2026)

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression. - Ziadi Y; Park T. (2026)

Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease - Johns Hopkins University (ClinicalTrials.gov, 2026)

Explainable AI framework for psilocybin depression treatment optimization - Sungheetha Akey; Rajesh Sharma R.; Aroba Oluwasegun Julius; Mahapatra Sheila; Mahendhiran P. D. (Frontiers in Computer Science, 2026)

Psychedelic Terminology Preference in the 2024 National Survey Investigating Hallucinogenic Trends (NSIHT). - Lyons FE; Rockhill KM; Fox EJ; Bemis EA; Black JC; Monte AA; Dart RC. (2026)

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder - Johns Hopkins University (ClinicalTrials.gov, 2026)

The renaissance of research on psychedelics in child and adolescent psychopharmacology. - Crocq MA; Auby P. (2026)

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. - Moreno FA; Allen KE; Wiegand CB; Dunne R; Prickett JI; Bayze B; Allen JJB. (2026)

Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review. - Sabé M; Grof P; Sackett NB; Tai S; Kryskow P; Bershad A; Turkington D; Buonarroti M; De Pieri M; Baniotopoulos P; Eskinazi M; Böge K; et al. (2026)

Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers. - McAlpine R; Jaglinska M; Jedlovszky K; Kuc J; Castro A; Piot A; Timmermann C; Skipper JI; Sacchet MD; Kamboj SK. (2026)

Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health - University of Alabama at Birmingham (ClinicalTrials.gov, 2026)

Psilocybin-facilitated Treatment for Chronic Pain - University of Alabama at Birmingham (ClinicalTrials.gov, 2026)

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study - Yale University (ClinicalTrials.gov, 2026)

Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs (PsyArXiv, 2026)

Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs - Luoma JB; Hoffman K; Wilson-Poe A; Levander X; Bazinet A; Cook R; McCarty D; Pertl K; Bielavitz S; Gregoire D; Wolf C; Jarlais DD; et al. (PsyArXiv, 2026)

Discovery of the closest free-living relative of the domesticated 'magic mushroom' Psilocybe cubensis in Africa. - Bradshaw AJ; Sharp C; Van Der Merwe B; Tremble KS; Dentinger BTM (Proceedings. Biological sciences, 2026)

Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders. - Chauhan SB; Akhtar N; Jain C; Singh I. (2026)

Age moderates the relationship between psychedelics use and mental health in naturalistic settings - Gregorio GD; Basset S; Manmohan H; Nixon WC; Pogaku A; Zhou J; Sanderson DJ; Lengieza ML; Bocchio M. (Research Square, 2026)

Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response - Floris G; Jefferson SJ; Rondeau J; Yu AL; Menniti FS; Kwan AC; De Aquino JP; Krystal JH; Pittenger C; Kaye AP. (bioRxiv, 2026)

An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD - Suzanne "Sue" Sisley MD (ClinicalTrials.gov, 2026)

Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review - Shore Ronald; Dobson Kat; Thomson Nina; Barnim Nigel; Bergman Hailey; Rideout Katie; McKeown Sandra; Olmstead Mary C.; Goldie Craig; Dumont Eric (Journal of Psychedelic Studies, 2026)

“Diversity makes the richness of humanity”: The emergence and persistence of mental imagery after self-reported psilocybin truffles intake in an autistic woman with “blind imagination” (aphantasia): A33-month retrospective case report - Rebecchi Kevin (Journal of Psychedelic Studies, 2026)

Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report - Shah S; Morrin H. (Research Square, 2026)